Summit Therapeutics stock

SMMT · NASDAQ · USD

Compare Summit Therapeutics
$10.67Change from previous close: −9.73%Absolute change: −$1.15

Close · November 17, 2026

Price history

−36.64% over the period

1 year: from $16.95 (November 17, 2025) to $10.74 (November 17, 2026), −36.64%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$10.74
October 30, 2026$16.03
September 30, 2026$16.91
August 31, 2026$13.62
July 31, 2026$13.02
June 30, 2026$14.57
May 29, 2026$17.54
April 30, 2026$21.46
March 31, 2026$18.96
February 27, 2026$16.59
January 30, 2026$14.48
December 31, 2025$17.49
November 28, 2025$17.89
November 17, 2025$16.95

At a glance

  • The company

    Biopharmaceutical company developing ivonescimab, a bispecific antibody combining immunotherapy and anti-angiogenesis for treating lung and colorectal cancers

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.19 (estimate -$0.29)

TickerLandia's take on Summit Therapeutics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$12.07
52-wk high$29.23

−63.50% from the 52-week high

Analysts · 17 analysts

Average target$29.54+176.88% vs. price

Buy 11 · Hold 6 · Sell 0 · Buy

TickerLandia Fingerprint: Summit Therapeutics

Compared with similar companies: very high risk, very weak momentum, and very low profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

3 dimensions without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Summit Therapeutics is pricier than similar companies

Summit Therapeutics's Price/book: 20.0, +52% against the median of a group of 10 similar companies (13.2).

Compared with 11 similar companies

Summit Therapeutics's metrics compared with similar companies
MetricSummit TherapeuticsPosition in the groupBand
Operating margin0.0%Middle
ROE-220.0%Low
Debt/equity0.04Low
Price/book20.0High
Net margin0.0%Middle

Grey band: the middle half of the group; tick: the median; dot: Summit Therapeutics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$0

Latest quarter · Q2 2026

Net income

-$215.7M

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$11.32B
EPS
-$1.06
Volume
5.56M
Daily trading
€80.14M
Dividend yield
0.00%

How Summit Therapeutics is changing

All results
  • Shares outstanding up 975.5% in 5 years

  • Profitable in 0 of 5 fiscal years

Returns

Summit Therapeutics returns

$1,000 invested in Summit Therapeutics 5 years ago, on November 17, 2021, would be worth $1,985 today: +98.52% in total, +14.70% per year. This is the price return only: dividends are excluded.

PeriodSummit TherapeuticsS&P 500$1,000 becomes
1 month−31.02%−3.17%$690
6 months−36.75%+0.11%$632
Year to date−38.59%+8.34%$614
1 year−36.64%+11.15%$634
3 years+456.48%+64.30%$5,565
5 years+98.52%+58.18%$1,985
10 years+2.29%+239.10%$1,023

Over the last 6 months it has done better than 3% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Summit Therapeutics: technical analysis

Summit Therapeutics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 70.9% below its all-time closing high ($36.70, April 24, 2025).

Trend
No clear trend
RSI (14 sessions)
32
Between 30 and 70
vs 200-session average
−33.80%

Active signals

  • New 52-week low.

    since November 16, 2026

  • Close below the low of the previous 55 sessions.

    since November 16, 2026

  • Golden cross: the 50-session average has crossed above the 200-session average.

    since November 4, 2026

  • Trading on November 17, 2026 was 2.3 times the 20-session average.

    since November 16, 2026

Support and resistance

Price areas where Summit Therapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$15.49+45.17%10 touches, last on September 28, 2026
  2. Resistance$14.31+34.08%5 touches, last on November 5, 2026
  3. Resistance$12.29+15.18%3 touches, last on August 17, 2026
  4. Last price$10.67
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
2.02
Volatility (60 sessions, annualised)
94.1%
Largest fall in the last year
−59.55%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Summit Therapeutics: seasonality

Average monthly price change over 12 years

+9.3%Jan+3.6%Feb+3.9%Mar+4.3%Apr+7.6%May−9.4%Jun+7.2%Jul−0.3%Aug+8.9%Sep−4.8%Oct−1.6%Nov+35.7%Dec

Over the last 12 years, the strongest month for Summit Therapeutics has been December: +35.68% on average, positive in 5 years out of 11. The weakest has been June: −9.37% on average, positive in 4 years out of 12. November, the current month, has been positive in 4 years out of 11 (−1.58% on average).

Show chart data
MonthAverageMedianPositive years
January+9.33%+15.65%6 of 11
February+3.56%−2.73%5 of 11
March+3.93%−2.78%5 of 11
April+4.26%−1.27%6 of 12
May+7.59%+0.26%6 of 12
June−9.37%−8.06%4 of 12
July+7.22%+2.67%7 of 12
August−0.26%−1.70%6 of 12
September+8.92%−0.56%5 of 12
October−4.82%−6.51%3 of 12
November−1.58%−1.55%4 of 11
December+35.68%−2.24%5 of 11

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Summit Therapeutics and its competitors

Its products are marketed in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of medicines. Its most advanced candidate, ivonescimab, is a bispecific antibody that combines PD-1 blockade with anti-angiogenesis activity, and it is being studied for non-small cell lung cancer and colorectal cancer.

Headquarters
Miami, United States
Employees
265
Founded
2003
Chief executive
Robert W. Duggan
Summit Therapeutics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Summit TherapeuticsSMMT$11.32B0.0%—−36.75%
Bio-TechneTECH$11.43B21.7%66.8+67.74%
BioMarin PharmaceuticalBMRN$11.09B16.3%146.8+12.93%
Madrigal PharmaceuticalsMDGL$9.93B-10.7%—−19.42%
Corcept TherapeuticsCORT$9.36B0.8%190.2+24.30%
Halozyme TherapeuticsHALO$14.67B56.8%38.3+42.98%

Same industry or related industries, similar size. Compare Summit Therapeutics with its competitors · Full profile